Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III

M. J. Reike, M. A. Ingersoll, D. C. Müller, T. C.M. Zuiverloon, T. Strandgaard, A. M. Kamat, S. B. Williams, R. Seiler, T. Todenhöfer, L. Dyrskjøt, R. Nawroth, P. Goebell, B. Schmitz-Dräger, J. P. Sfakianos, J. Meeks, A. Horowitz, P. C. Black*

*Corresponding author for this work

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperReviewResearchpeer-review

Abstract

Bacillus Calmette-Guerin (BCG) remains the only FDA-approved first-line therapy in patients with high-risk non-muscle invasive bladder cancer. Recurrences, even after adequate BCG therapy, are common and the efficacy of second-line therapies remains modest. Therefore, early identification of patients likely to recur and treatment after recurrence remain critical unmet needs in the clinical care of bladder cancer patients. To address these deficits, a better understanding of the mechanisms of resistance to BCG-therapy is needed. The virtual update of the International Bladder Cancer Network (IBCN) on the biology of response to BCG focused on potential mechanisms and markers of resistance to intravesical BCG therapy. The insights from this meeting will be highlighted and put into context of previously reported mechanisms of resistance to BCG in this review.

Original languageEnglish
JournalUrologic Oncology: Seminars and Original Investigations
Volume41
Issue5
Pages (from-to)211-218
Number of pages8
ISSN1078-1439
DOIs
Publication statusPublished - May 2023

Keywords

  • Bacillus Calmette-Guerin (BCG)
  • Bladder cancer
  • Immunotherapy

Fingerprint

Dive into the research topics of 'Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III'. Together they form a unique fingerprint.

Cite this